Fibroblast growth factor (FGF) 21 is a natural hormone that modulates glucose, lipid, and energy metabolism. Previously, we engineered an Fc fusion FGF21 variant with two mutations, Fc-FGF21 (RG), to extend the half-life and reduce aggregation and in vivo degradation of FGF21. We now describe a new variant developed to reduce the extreme C-terminal degradation and improve the binding affinity to b-Klotho. We demonstrate, by introducing one additional mutation located at the C terminus of FGF21 (A180E), that the new molecule, Fc-FGF21(RGE), has gained many improved attributes. Compared with Fc-FGF21(RG), Fc-FGF21(RGE) has similar in vitro potency, preserves b-Klotho dependency, and maintains FGF receptor selectivity and cross-species reactivity. In vivo, Fc-FGF21(RGE) showed reduced susceptibility to extreme C-terminal degradation and increased plasma levels of the bioactive intact molecule. The circulating half-life of intact Fc-FGF21(RGE) increased twofold compared with that of Fc-FGF21(RG) in mice and cynomolgus monkeys. Additionally, Fc-FGF21(RGE) exhibited threefold to fivefold enhanced binding affinity to coreceptor b-Klotho across mouse, cynomolgus monkey, and human species. In obese and diabetic mouse and cynomolgus monkey models, Fc-FGF21(RGE) demonstrated greater efficacies to Fc-FGF21(RG), resulting in larger and more sustained improvements in multiple metabolic parameters. No increased immunogenicity was observed with Fc-FGF21(RGE). The superior biophysical, pharmacokinetic, and pharmacodynamic properties, as well as the positive metabolic effects across species, suggest that further clinical development of Fc-FGF21(RGE) as a metabolic therapy for diabetic and/or obese patients may be warranted. (Endocrinology 158: 1314(Endocrinology 158: -1327(Endocrinology 158: , 2017 
T ype 2 diabetes affects .400 million individuals worldwide and is the leading cause of kidney failure, nontraumatic lower-limb amputations, and new cases of blindness among adults (1) . Despite the prevalence of therapeutic options available to treat this disease, a large percentage of patients with diabetes are not able to achieve the recommended American Diabetes Association target of hemoglobin A1c levels , 7% (2). Patients with type 2 diabetes often demonstrate associated metabolic comorbidities, such as obesity, hyperlipidemia, and hypertension (3) . Therefore, novel agents that provide enhanced glucose-lowering, increased cardiovascular benefits and reduced hypoglycemia and weight gain are needed. Fibroblast growth factor (FGF) 21 is an attractive drug target for type 2 diabetes and metabolic syndrome. It modulates glucose, lipid, and weight metabolism and demonstrates positive effects on multiple metabolic parameters (4) (5) (6) . Compared with existing therapies, FGF21 has a strong insulin-sensitizing mechanism without increases in hypoglycemia, edema, or weight gain (6, 7) .
FGF21 is an ;20-kDa secreted polypeptide sharing similar homology with other FGFs (8) . FGF21 is preferentially expressed in tissues associated with metabolic function, including the liver, pancreas, and adipose tissues (8, 9) . Upon secretion, FGF21 acts on a receptor complex consisting of a coreceptor, b-Klotho, and a canonical fibroblast growth factor receptor (FGFR) located on the surface of the plasma membrane (10) . FGF21 interacts with b-Klotho, signals through the C isoforms of the FGFR (11) , and subsequently activates FGFR tyrosine kinase, leading to intracellular signaling cascades, including activation of the mitogen-activated protein kinase pathway (11) .
Administration of FGF21 in diabetic and obese rodent and monkey models resulted in a remarkable improvement of the metabolic state of treated animals (5, 6, 12, 13) . Currently, several FGF21 molecules are under clinical development, and data from phase 1b were reported for two compounds (14, 15) . LY2405319 is a short-acting FGF21 analog and requires daily administration (14) . PF-05231023 is formed by conjugating FGF21 to the Fab domain of a scaffold antibody (15) . Both compounds decreased plasma triglyceride and cholesterol levels, increased high-density lipoprotein (HDL) cholesterol levels, and reduced body weight in obese and diabetic patients. However, the glucoselowering effects of these compounds were minimal (14) or not observed (15) . The short half-life of LY2405319 (16) and the susceptibility of PF05231023 to both N-and C-terminal degradation may explain the insufficient glycemic effect (17) .
In this study, we report a long-acting, stable, and efficacy-enhanced novel Fc-FGF21 fusion protein suitable for weekly or biweekly subcutaneous administration. This molecule is derived from a previously engineered Fc-FGF21 (RG) molecule (13, 18) , by introducing one mutation at the C terminus of FGF21 (A180E). The three specific modifications (L98R, P171G, and A180E) reduce the aggregation and proteolytic degradation of FGF21 and improve binding affinity of FGF21 to its coreceptor b-Klotho.
Materials and Methods

Plasmid construction, protein expression, and purification
Targeted engineering at the C terminus of FGF21 to improve its resistance to proteolysis while enhancing its ability to bind to b-Klotho was undertaken. Plasmid constructs encoding various FGF21 proteins, site-directed mutagenesis to introduce point mutations, plasmid transformation, protein expression, and purification from a bacteria system were previously described (18) .
Animals
All mouse studies were conducted at Amgen (Thousand Oaks, CA) and were approved by the Institutional Animal Care and Use Committee.
The efficacy assessment in cynomolgus monkeys was conducted at Yunnan Laboratory Primate (Kunming, Yunnan, People's Republic of China). All procedures were in compliance with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare.
b-Klotho binding assay
The binding activity of FGF21 variants to mouse, human, and cynomolgus monkey b-Klotho was determined by BIAcore 3000 instrument (GE Healthcare, Piscataway, NJ). The study was conducted in a solution equilibrium binding assay by measuring the ability of FGF21 variants to prevent b-Klotho from binding to the biotinylated FGF21 immobilized on the chip surface of BIAcore (19) .
In vitro activity assays
The Elk1-luciferase reporter assay was conducted in naive human 293T cells or 293T cells stably expressing human b-Klotho or in AM-1/D Chinese hamster ovary cells stably expressing both human b-Klotho and human FGFR1c as described previously (18) . For the glucose uptake assay, 3T3L1 preadipocytes (American Type Culture Collection CL-173) were cultured and induced to differentiate. Differentiated 3T3-L1 adipocytes were incubated for 72 hours with FGF21 variants and assayed for glucose uptake as described (20) .
Receptor specificity assay in L6 cells
L6 rat myoblast cells were plated and cotransfected with human b-Klotho and each individual FGFR isoform. Following overnight serum starvation, cells were stimulated with different concentrations of FGF21 molecules for 10 minutes, snap frozen, and phosphorylated extracellular signal-regulated kinase (ERK) and total ERK from cell lysates were measured using a Meso Scale Discovery assay (20) . All experiments were run in duplicate.
Pharmacokinetic and stability studies in cynomolgus monkeys and mice Fc-FGF21(RG) and Fc-FGF21(RGE) were injected IV into male cynomolgus monkeys (Valley Biosystems, West Sacramento, CA) at 23.5 mg/kg or male C57BL/6 mice (Charles River Laboratories, San Diego, CA) at 20 mg/kg. Blood samples were collected from mice and monkeys at 5 minute and at 2 and 6 hours and at 1, 2, 4, and 7 days postdose. In monkeys, additional blood samples were collected at 10, 14, and 21 days postdose. Plasma samples were divided into aliquots for ligandbinding mass spectrometry analyses and enzyme-linked immunosorbent assay (ELISA).
Detailed methodology for ligand-binding matrix-assisted laser desorption ionization (LB-MALDI), ligand-binding digestion/ multiple reaction monitoring (MRM) analyses, and the quantitative determinations of intact bioactive FGF21 analogs in biomatrices have been reported (18, 21) .
Pharmacokinetic analysis
Pharmacokinetic parameters such as area under the (concentration/time) curve (AUC) and terminal half-life were estimated from FGF21 analog plasma concentration data via noncompartmental analysis using WinNonlin Professional software version 4.1e (Pharsight, Mountain View, CA). The detailed analysis was done as described previously (22) .
Efficacy studies in mice
General methodologies for studies in db/db and DIO mice were described previously (18) . db/db mice were randomized into treatment groups and intraperitoneally (IP) administered with vehicle, 2.3 mg/kg Fc-FGF21(RG), or 2.3 mg/kg Fc-FGF21 (RGE). Blood glucose levels and body weights were measured at indicated time points before and after compound injection. DIO mice were randomized into treatment groups based on body weight and blood glucose values. Vehicle, Fc-FGF21 (RG) (0.3, 1, and 3 mg/kg) or Fc-FGF21(RGE) (0.3, 1, and 3 mg/kg) were IP injected once a week. An age-matched lean mouse group receiving vehicle was included as a control. Body weight was measured twice weekly and food intake weekly. In a separate study, DIO mice were IP injected with vehicle [once a week [QW]), Fc-FGF21(RG) [3 mg/kg, QW or every 2 weeks (Q2W)], or Fc-FGF21(RGE) (3 mg/kg, QW or Q2W). Body weight was measured twice weekly, and a glucose tolerance test (GTT) was performed on day 28. The study was terminated on day 31.
Efficacy studies in cynomolgus monkeys
Male cynomolgus monkeys were prescreened using oral GTT (OGTT) profiles, and those demonstrating relatively impaired glucose tolerance and obesity were selected for this study. Monkeys were stratified into three groups receiving either vehicle (n = 14), Fc-FGF21(RG) (n = 13), or Fc-FGF21(RGE) (n = 13) based on baseline OGTT profile (AUC and curve shape), baseline fasting blood glucose, triglyceride levels, and body weight. The stratification assured comparable baseline values for each of the characteristics. For all OGTTs performed, monkeys were administered orally D-glucose at 4 g/kg. Blood samples were collected at 23 minutes (before D-glucose administration) and at 15, 30, 60, 120, and 180 minutes (after D-glucose administration) for plasma glucose and insulin measurements. 
Analysis of drug concentrations and antidrug antibody
Statistical analysis
Data are presented as means 6 standard error of the mean (SEM). Monkey data were analyzed using SAS version 9.2 (SAS Institute, Cary, NC). Data were log transformed prior to statistical analysis. The mixed effect model methodology was used as previously described (13) .
Results
Generation of Fc-FGF21(RGE)
We previously engineered an Fc-FGF21(RG) molecule with two engineered point mutations. The L98R mutation reduced the aggregation of FGF21 at high concentrations or temperature; the P171G mutation eliminated the susceptibility of in vivo proteolysis at the peptide bond between Pro 171 and Ser
172
. After eliminating the internal clipping at position 171, new cleavage sites generating one to three residue losses from the extreme C terminus were observed when Fc-FGF21(RG) was administered to mice and monkeys. The extreme C-terminal clippings deactivate the biological activity of FGF21 as severely as the 10-amino acid truncation at Pro 171 (19) .
Screening of compounds with targeted engineering at the C terminus designed to improve resistance to proteolysis revealed a lead variant with a glutamic acid substitution of alanine at position 180 (A180E). This substitution improved C-terminal resistance to proteolysis and enhanced the binding activity to b-Klotho. The structural feature of the new variant, Fc-FGF21 (RGE), is shown in Fig. 1 .
In vivo stability
One of the main modes of metabolism of Fc-FGF21 (RG) is the carboxypeptidase-like breakdown of the C terminus that occurred from 24 to 168 hours [ Fig. 2(a) , left panel]. The peaks represent the incompletely resolved mixture of the loss of one to three C-terminal residues. Conversely, for Fc-FGF21(RGE), the spectra show fewer peaks directly adjacent to the left of the parent peak, indicating less extensive C-terminal degradation. A significant amount of intact was observed even at 168 hours [ Fig 
Pharmacokinetics in mice and cynomolgus monkeys
Fc-FGF21(RGE) displayed superior exposure relative to Fc-FGF21(RG), as shown by an AUC increase of 54% and 21% in mice and monkeys, respectively ( 
b-Klotho binding activity
There was no difference between the binding of Fc-FGF21(RG) and native FGF21 to either human or mouse b-Klotho (Fig. 3) . Fc-FGF21(RGE) consistently demonstrated increased binding activity to b-Klotho of human (fourfold), mouse (fivefold), and cynomolgus monkey (threefold) relative to Fc-FGF21(RG) or native FGF21 (Fig. 3) . The 50% effective concentration (EC 50 ) of b-Klotho binding affinity for Fc-FGF21(RGE) was 6.7, 0.3, and 10 nM for human, mouse, and monkey b-Klotho, respectively.
In vitro cell-based functional activity
The ability of Fc-FGF21(RGE) to activate an Elk1-driven luciferase reporter was observed in 293 cells transfected with b-Klotho but not in naive 293 cells. This is similar to results observed for native FGF21 and other Fc fusion FGF21s, and is in contrast to results observed with FGF1 [ Fig. 4(a) and 4(b) ]. The biological activity of Fc-FGF21(RGE) was similar to that of Fc-FGF21 wildtype fusion and Fc-FGF21(RG) but slightly lower than that of native FGF21, as measured by the Elk1-luciferase reporter assay in cells expressing b-Klotho alone [ Fig. 4(b) ] or coexpressing b-Klotho and FGFR1c [ Fig. 4(c)] .
In a human primary adipocyte assay, the ability of Fc-FGF21(RGE) to stimulate ERK phosphorylation was not strongly different from that of Fc-FGF21(RG) or native FGF21 [ Fig. 4(d) ]. Similar to the results observed in the Elk1-luciferase reporter assay [ Fig. 4(b) and 4(c) ], Fc-FGF21(RGE) showed partial activity with a slight right shift in potency compared with wild-type FGF21 in stimulating glucose uptake into 3T3-L1 adipocytes [ Fig. 4(e) ].
The FGFR specificity for Fc-FGF21(RGE) was evaluated in the rat myoblast cell line L6. Similar to native FGF21, Fc-FGF21(RGE) preferentially stimulated ERK phosphorylation in L6 cells expressing FGFR1c, 2c, and 3c with b-Klotho, whereas it displayed very weak activity in L6 cells expressing FGFR4/b-Klotho [ Fig. 4(f) ]. The activity on FGFR4 was only seen at the high doses tested for both native FGF21 and Fc-FGF21(RGE) [Fig. 4(f) ]. The cross-species activity of Fc-FGF21(RGE) was also determined by coexpressing b-Klotho and FGFR1c from human, mouse, rat, or cynomolgus monkey origins in IMCD3 cells. Fc-FGF21(RGE) was functionally active in IMCD3 cells expressing these receptors from all four species (data not shown).
Efficacy in mice
A single injection of Fc-FGF21(RGE) in db/db mice produced a greater and more durable effect on reductions of blood glucose and body weight gain than did In a subsequent efficacy study, Fc-FGF21(RGE) was efficacious at either QW or Q2W dosing, whereas Fc-FGF21(RG) was only mildly efficacious at QW schedule based on improvement of GTT and reduction of body weight [ Fig. 5(j) and 5(k) ]. This suggests that Fc-FGF21 (RGE) may require twofold less frequent dosing than Fc-FGF21(RG).
Efficacy in obese male cynomolgus monkeys
The study design, injection schedule and dose levels, and data collection time points are summarized in Fig. 6(a) .
Fc-FGF21(RGE) treatment of obese, male cynomolgus monkeys with impaired glucose tolerance resulted in a statistically significant reduction of fasting blood glucose levels, whereas an effect of Fc-FGF21(RG) on blood glucose was not observed [ Fig. 6(b) ]. Both Fc-FGF21 (RGE) and Fc-FGF21(RG) caused a significant reduction in fasting plasma insulin and amylin levels, with near maximum effect achieved after the first injection at 0.3 mg/kg for each compound [ Fig. 6 (c) and 6(d)]. Administration of Fc-FGF21(RGE) and Fc-FGF21(RG) resulted in a rapid and sustainable reduction in fasting plasma triglyceride levels; the near maximum effect was reached after the first injection of each compound [ Fig. 6(e) ]. Fc-FGF21(RGE) was superior to Fc-FGF21(RG) in triglyceride reduction at all doses tested and during the washout period [ Fig. 6(e) ]. HDL cholesterol levels were significantly increased by 40% from baseline in monkeys treated with Fc-FGF21(RGE), compared with a 29% or 22% increase from baseline in monkeys treated with Fc-FGF21(RG) or vehicle [ Fig. 6(f) ]. Elevations of HDL cholesterol did not reach significance for any time point in monkeys treated with Fc-FGF21(RG) in comparison with monkeys treated with vehicle. Glucagon levels were significantly reduced from days 47 to 70 by 30% to 40% (P , 0.05) in both Fc-FGF21(RG) and Fc-FGF21(RGE) groups relative to the vehicle group [ Fig. 6(g) ].
Fc-FGF21(RGE) improved oral glucose tolerance in monkeys at each dose tested from 0. A significant reduction in morning and afternoon meal intake was observed for the Fc-FGF21(RGE) group [ Fig. 7 (d) and 7(e)] as early as 4 days after the first injection at 0.3 mg/kg. It sustained for the next 3 weeks and subsided around day 28, after 4 weeks of Fc-FGF21(RGE) treatment. It recovered to near pretreatment levels as the dose of Fc-FGF21(RGE) was escalated to 3 mg/kg [ Fig. 7 (d) and 7(e)]. Three monkeys from the Fc-FGF21(RGE) group exhibited a severe reduction in food consumption. These three monkeys were maintained at 0.3 mg/kg for the entire study. Data collected from these three monkeys after day 21 were excluded from the analyses of efficacy and exposure. In contrast to Fc-FGF21(RGE), Fc-FGF21(RG) treatment did not show a consistent effect on food intake relative to vehicle [ Fig. 7(d) and 7(e) ].
Analysis of drug concentrations and antidrug antibodies in monkeys
Plasma concentrations of compounds were measured from blood samples collected predose and during the dose-escalation (5 days after each injection) and washout periods. Compounds were not detectable in vehicletreated monkeys or in predose samples (data not shown). As doses of the Fc-FGF21 compounds were escalated, the lean, n = 7; DIO groups, n = 9; washout: lean, n = 3; DIO groups, n = 5. (i) Lean, n = 3 to 7; DIO-Veh n = 4-8; Fc-FGF21(RG) groups, n = 3 to 9; Fc-FGF21(RGE) groups, n = 1 to 9. (j and k) n = 8 per group. One-way analysis of variance followed by a post hoc Fisher's probable least-squares difference test was used to determine statistical significance of the difference in comparison with DIO vehicle-treated group. *P , 0.05, **P , 0.01, and *** P , 0.001. Veh, vehicle. doi: 10.1210/en. https://academic.oup.com/endo , n = 12 to 13; (RGE), n = 10 to 13. Data were log transformed and a mixed effects model, which included group as a fixed effect and baseline as a covariate, was applied using SAS v9.2. *P , 0.05, **P , 0.01, and ***P , 0.001 vs vehicle control group. Veh, vehicle. At each equivalent dose level, Fc-FGF21(RGE) showed about threefold higher plasma concentrations than did Fc-FGF21(RG) [ Fig. 7(f) ]. There was minimal accumulation for both compounds as demonstrated by the steady concentrations between sampling times within each dose phase [ Fig. 7(f) ]. During the washout period, plasma concentrations of compounds declined with time, but this was slower for Fc-FGF21(RGE) than Fc-FGF21(RG) [ Fig. 7(f) ]. Anti-drug (human Fc-FGF21s) antibody measurements of the vehicle-treated group showed that one of 14 animals (7%) had pre-existing antibodies detectable at baseline and at days 19, 40, 84, and 133. In the Fc-FGF21 (RGE)-treated group, seven of 13 animals (54%) developed antibodies after initiation of treatment, whereas eight of 13 animals (62%) in the Fc-FGF21(RG)-treated group did [ Fig. 7(g) ]. Antibody specificity analysis indicated that most of the antibodies were specific for FGF21, but one positive animal in each treated group also exhibited anti-IgG1 Fc reactivity [ Fig. 7(g) ]. The pharmacokinetic profile of two monkeys treated with Fc-FGF21(RG) appeared to be impacted by the development of anti-Fc-FGF21(RG) antibodies. The pharmacokinetic profiles of all other monkeys positive for antidrug antibodies were similar to monkeys who did not develop antibodies. Neutralizing activity was not assessed for this study.
Discussion
Although several therapeutic options are available for type 2 diabetes, more than ;50% of patients with diabetes do not achieve the recommended glycemic control even when treated with intensive combination therapies (2) . In this study, we describe the development and characterization of a recombinant Fc fusion protein that targets the FGF21 pathway. It represents a novel mechanism of action, distinct from currently available therapies. In addition to improving glucose levels, this protein also lowered both lipid levels and body weight and offered a more convenient dosing schedule.
Activation of the FGF21 pathway has demonstrated diverse metabolic benefits, including lowering blood glucose levels, reducing triglyceride and low-density lipoprotein cholesterol, raising HDL cholesterol, decreasing body weight, and improving hepatosteatosis (5, 6) . Also, FGF21 has been shown to prevent aging and reduce cardiovascular risks (23, 24) . To augment its therapeutic potential, we previously engineered an Fc fusion FGF21 analog, Fc-FGF21(RG), to improve the pharmacokinetic, pharmacodynamic, and pharmaceutical properties of the native protein (18) . Stability analyses indicated that new degradation products were detected rapidly following administration of Fc-FGF21(RG) in mice and monkeys. A resulting substantial reduction in binding affinity to b-Klotho and potency when compared with native FGF21 suggested that the extreme C-terminal sequence is critical to the full biological activity of FGF21. Identification of a re-engineered Fc-FGF21(RG) with an alanine to glutamic acid substitution at position 180 (A180E) showed decreased proteolytic processing at the C terminus and increased plasma concentrations and residence time. These new findings suggest that negative charge of the acidic amino acid may play a role in stabilizing FGF21 by blocking the access of protease to the C terminus.
The nature of the protease is unknown but may involve carboxypeptidase activity, which removes amino acids one at a time from the C terminus (25) . Recently, three groups simultaneously reported that the fibroblast activation protein (FAP) was the specific endopeptidase responsible for the cleavage of FGF21 at Pro 171 (26) (27) (28) . FAP is a member of type II transmembrane serine proteases and also exists as a truncated soluble form in the circulation. It is a prolyl peptidase that cleaves specifically after proline with a recognition motif of Gly-Pro (27) . This motif is present in the FGF21 polypeptide sequence (Gly 170 -Pro 171 ) and was demonstrated to be cleaved by FAP. The P171G mutation abolished the FAP activity and prevented the site-specific cleavage (27) . FAP is closely related to DPP-IV, which was the primary protease identified as being responsible for the N-terminal cleavage of FGF21 at Pro-2 and Pro-4 (28) . Further identification of enzymes that process the C terminus of FGF21 will continue to inform methods to optimize the pharmacokinetics and pharmacodynamics of this protein.
Fc-FGF21(RGE) demonstrated a consistent increase in the binding activity toward mouse, cynomolgus monkey, and human b-Klotho by threefold to fivefold. However, the in vitro potency of Fc-FGF21(RGE) was not different from that of Fc-FGF21(RG) in recombinant human primary adipocyte cells overexpressing b-Klotho alone or with FGFR1c. These results are in contrast with those of C-terminal deletion mutants tested in a similar cell-based assay (19) . One possibility is that the increased activity is difficult to measure in cells where the coreceptor and/or signaling receptor were overexpressed. Although the receptors are expressed at endogenous levels in human primary adipocytes, the variability of the primary cells and small magnitude of response made the quantification difficult. Alternatively, b-Klotho plays a permissive role for FGF21 to bind to and activate FGFR. Beyond a certain threshold, the increased binding activity to b-Klotho would not translate to increased functional activity. Nevertheless, Fc-FGF21(RGE) retained the biological activity similarly to Fc-FGF21(RG). It also demonstrated similar FGFR specificity and cross-species reactivity as for native FGF21.
An ELISA assay showed that the half-life of Fc-FGF21 (RGE) was approximately twofold increased from that of Fc-FGF21(RG) in both mice and monkeys, as a result of improved in vivo stability. The plasma concentrations of Fc-FGF21(RGE) were consistently threefold higher than those of Fc-FGF21(RG) when administered at an equivalent dose in monkeys. The disappearance of Fc-FGF21(RGE) from plasma was also slower than that of Fc-FGF21(RG).
The increased exposure and half-life extension were corroborated with enhanced and prolonged efficacy. A potential of dosing convenience by reducing injection frequency while maintaining efficacy was also achievable. In multiple mouse models following single or multiple injections, Fc-FGF21(RGE) consistently demonstrated superiority to Fc-FGF21(RG) in lowering blood glucose levels, improving glucose tolerance, reducing triglyceride and cholesterol levels, and decreasing body weight. The increased efficacy not only reflected a longer duration of action but also a greater magnitude of effects. Furthermore, the results suggest that Fc-FGF21 (RGE) may be suitable for Q2W administration, rather than QW administration, and at doses threefold to fivefold lower than Fc-FGF21(RG) to achieve a similar efficacy.
Fc-FGF21(RGE) also outperformed Fc-FGF21(RG) for nearly all the parameters measured in obese cynomolgus monkeys. The monkeys selected for the study were obese and aging with a presentation of relatively high AUC of OGTT and fasting glucose levels during the prescreen. In this model, Fc-FGF21(RGE) reduced fasting and fed plasma glucose levels (data not shown) and improved glucose tolerance, whereas Fc-FGF21(RG) had a mild effect, although both compounds strongly reduced plasma insulin levels and improved insulin sensitivity during OGTT. In lipid parameters, Fc-FGF21(RGE) also exerted stronger effects on plasma triglyceride reduction and HDL cholesterol elevation than did Fc-FGF21(RG). Plasma insulin, amylin, and triglycerides were very sensitive to FGF21 treatment, and near maximum reductions were achieved after the first injection of each compound. With the dose escalation, the effect was sustained at each maximal level, suggesting that 0.3 mg/kg is the maximum effective dose for each compound for these parameters.
Both compounds caused marked reductions in body weight, body mass indexes, and abdominal circumference, with Fc-FGF21(RGE)-treated monkeys significantly greater in body weight reduction than Fc-FGF21 (RG)-treated monkeys. A transient reduction of food intake was observed for Fc-FGF21(RGE)-treated monkeys in the initial 3 weeks of the treatment, but the effect subsided and the food consumption recovered to near baseline levels. Furthermore, monkeys treated with Fc-FGF21(RG) consumed similar amounts of food as did monkeys in the vehicle group, while exhibiting substantial weight loss. These results suggest that the reduced food intake does not fully account for the weight loss observed in monkeys following FGF21 administration. The reduction in food intake was not dose-dependent and could be overcome through an undefined adaptation mechanism.
In mice, most FGF21 compounds showed no suppressive effect on food intake (5, 6). Increased energy expenditure and basal metabolic rate were identified as major mechanisms responsible for the body weight reduction in mice (6) . To our knowledge, Fc-FGF21(RGE) is the first FGF21 compound that reduced food intake in DIO mice. This effect was transient and attenuated at the fourth week of treatment, similarly to what was observed in monkeys. Therefore, there appears to be no fundamental difference between species, but rather the difference in response (i.e., reduced food intake) is likely compound specific. The mechanism underlying FGF21 effect on food intake and body weight is likely a centrally mediated mode of action. Native FGF21 has been reported to be able to passive diffusion into the brain (29) and its receptors, including b-Klotho and FGFR1c, are expressed in several brain regions (30) , such as hypothalamus, where food intake is controlled. Although our compound has a larger molecular mass than that of native FGF21 and is expected to have limited ability to cross the blood-brain barrier, Fc fusion protein and antibody have inherent penetration with an estimated 0.1% to 0.2% of circulating levels found in brain at steady-state concentrations (31) . Additionally, FGF21 acts in the liver and pancreas, and these tissues have been shown to crosstalk with brain and participate in central nerve system-mediated control of food intake. Further studies are needed to elucidate the contribution of Fc-FGF21(RGE) on food intake.
The improved C-terminal stability may enable a stronger and longer receptor occupancy and engagement and render Fc-FGF21(RGE) more efficacious. During the washout period, body weigh gradually returned toward baseline values in both compound-treated mice. Overeating was observed in both treated groups, which may reflect a compensatory mechanism to facilitate the body weight recovery.
As expected, more than half of the monkeys treated with human Fc-FGF21(RG) or Fc-FGF21(RGE) developed antidrug antibodies with more reactivity toward the FGF21 than the Fc portion of the protein. However, no difference in immunogenicity was observed between Fc-FGF21(RG) and Fc-FGF21(RGE), suggesting that the additional A180E mutation did not create neoepitopes or nontolerant epitopes.
In summary, we developed a novel Fc fusion FGF21 analog by conjugating a human Fc fragment to a modified FGF21 protein containing three engineered mutations to improve its stability in vitro and in vivo, and to enhance its binding affinity to b-Klotho. Fc-FGF21(RGE) is a potent and efficacious long-acting FGF21 molecule, with attributes favorable to Fc-FGF21(RG), including activation of b-Klotho-dependent FGFR signaling with sub-to singledigit nanomolar potency, preservation of the FGFR selectivity toward the C isoforms, and maintenance of crossspecies reactivity in rodent, monkey, and human cells. Additionally, Fc-FGF21(RGE) produced robust and sustained metabolically beneficial effects in rodent and nonhuman primate models. Furthermore, Fc-FGF21(RGE) displayed a robust reduction in glucose and triglyceride levels, modification of lipoproteins, and antiobesity effect in both obese, insulin-resistant mice and diabetic mice, as well as in obese monkeys. The cross-species positive metabolic effects of Fc-FGF21(RGE) coupled with its improved biophysical and in vivo stability and dosing convenience warrant further investigation of this molecule for treatment of human metabolic disorders and its effects on glucose lowering.
